The effect of hepcidin on components of metabolic syndrome in chronic kidney disease: a cross-sectional study

Abstract

SUMMARY BACKGROUND Hepcidin is an important regulator of iron homeostasis. OBJECTIVES This cross-sectional study was conducted to evaluate the association between hepcidin and components of metabolic syndrome in patients with chronic kidney disease (CKD). DESIGN AND SETTING 103 CKD patients and 59 healthy volunteers were included in the study from the University Hospital. METHODS Serum hepcidin levels were measured by enyzme-linked immunosorbent assay (ELISA) test. As for the study parameters, age, sex, body mass index, renal diseases, serum biochemistry, complete blood count, iron and total iron-binding capacity, ferritin, high-sensitive C-reactive protein (hsCRP), C- reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. RESULTS The mean age of the patients was 58.63 ± 11.8 years. Hepcidin level was significantly associated with hypertension and higher uric acid levels (P < 0.05). There was a positive correlation between hepcidin and urea, uric acid, creatinine, ferritin, CRP, ESR, phosphorus, triglyceride, low-density lipoprotein (LDL), proteinuria and albuminuria in 24-hour urine collection. A negative correlation was found between hepcidin and estimated glomerular filtration rate (eGFR), hemoglobin, hematocrit, calcium, 25 OH vitamin D, pH, and bicarbonate levels. CONCLUSION Hepcidin, a well-known hormone regulator of iron metabolism, may play an important role in the pathogenesis of metabolic syndrome in patients with CKD, and further studies might delineate in-depth its potential as a promising early marker in these patients.

Alzheimer's disease as an innate autoimmune disease (AD2): A new molecular paradigm

“…Beyond infection as an obvious trigger, trauma, 14 ischemia, 15 pollution, 16 depression, 17 and metabolic syndrome 18 are other described stimuli for AMP release via PAMP/DAMP overlaps (and likewise are documented risk factors for AD). Such diverse stimuli are potentially noxious to the brain and thus trigger an immune response that includes the release of Aβ as an AMP/immunomodulator.…”

A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report

“…Iron also regulates metabolism in most tissues involved in fuel homeostasis, with adipocytes playing an iron-sensing role. The underlying molecular mechanisms mediating these effects are numerous and not completely understood, but include oxidative stress, modulation of adipokines, and intracellular signal transduction systems [ 33 , 57 ]. Iron deposition also induces insulin resistance by inhibiting glucose uptake in fat and muscle tissues, and by reducing the capacity of the liver to extract insulin, which results in an abnormal increase in hepatic glucose production [ 58 ].…”

“…In HH, the accumulation of iron in the liver, heart, and pancreas leads to cirrhosis, heart failure, and diabetes, respectively. Even mild iron overload might aggravate insulin resistance, diabetes, atherosclerosis, colonic neoplasia, and NAFLD [ 51 , 52 , 57 , 59 ]. Increased oxidative stress is widely regarded as a key factor in the progression and deterioration of chronic liver diseases [ 49 ].…”

Relation between erythropoietin resistance and metabolic syndrome in hemodialysis patients: A multicentric propensity score matched analysis

“…For example, hepcidin was found to be related to MetS in patients with chronic kidney disease. 20 In addition, oxidative stress was suggested to play a determinant role in biometabolic derangements in MetS. 21…”